PMC:7283670 / 59847-61046 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T217","span":{"begin":836,"end":842},"obj":"Body_part"},{"id":"T218","span":{"begin":850,"end":856},"obj":"Body_part"},{"id":"T219","span":{"begin":861,"end":884},"obj":"Body_part"}],"attributes":[{"id":"A217","pred":"fma_id","subj":"T217","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A218","pred":"fma_id","subj":"T218","obj":"http://purl.org/sig/ont/fma/fma312401"},{"id":"A219","pred":"fma_id","subj":"T219","obj":"http://purl.org/sig/ont/fma/fma45662"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T138","span":{"begin":836,"end":842},"obj":"Body_part"},{"id":"T139","span":{"begin":850,"end":856},"obj":"Body_part"},{"id":"T140","span":{"begin":861,"end":884},"obj":"Body_part"},{"id":"T141","span":{"begin":867,"end":884},"obj":"Body_part"}],"attributes":[{"id":"A138","pred":"uberon_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A139","pred":"uberon_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"},{"id":"A140","pred":"uberon_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"A141","pred":"uberon_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T358","span":{"begin":78,"end":86},"obj":"Disease"},{"id":"T359","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"T360","span":{"begin":776,"end":784},"obj":"Disease"}],"attributes":[{"id":"A358","pred":"mondo_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A359","pred":"mondo_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A360","pred":"mondo_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T566","span":{"begin":195,"end":197},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T567","span":{"begin":440,"end":444},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T568","span":{"begin":456,"end":457},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T569","span":{"begin":600,"end":606},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T570","span":{"begin":861,"end":884},"obj":"http://purl.obolibrary.org/obo/UBERON_0001558"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T54594","span":{"begin":103,"end":112},"obj":"Chemical"},{"id":"T97769","span":{"begin":240,"end":249},"obj":"Chemical"},{"id":"T20676","span":{"begin":277,"end":286},"obj":"Chemical"},{"id":"T92853","span":{"begin":294,"end":304},"obj":"Chemical"},{"id":"T46415","span":{"begin":365,"end":383},"obj":"Chemical"},{"id":"T20639","span":{"begin":482,"end":500},"obj":"Chemical"},{"id":"T47677","span":{"begin":1104,"end":1108},"obj":"Chemical"}],"attributes":[{"id":"A10109","pred":"chebi_id","subj":"T54594","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A13376","pred":"chebi_id","subj":"T97769","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A84865","pred":"chebi_id","subj":"T20676","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A6712","pred":"chebi_id","subj":"T92853","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A3545","pred":"chebi_id","subj":"T46415","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A89179","pred":"chebi_id","subj":"T20639","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A41889","pred":"chebi_id","subj":"T47677","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T44","span":{"begin":885,"end":895},"obj":"http://purl.obolibrary.org/obo/GO_0046903"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T628","span":{"begin":0,"end":445},"obj":"Sentence"},{"id":"T629","span":{"begin":446,"end":560},"obj":"Sentence"},{"id":"T630","span":{"begin":561,"end":599},"obj":"Sentence"},{"id":"T631","span":{"begin":600,"end":790},"obj":"Sentence"},{"id":"T632","span":{"begin":791,"end":1199},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1885","span":{"begin":964,"end":976},"obj":"Species"},{"id":"1886","span":{"begin":1056,"end":1068},"obj":"Species"},{"id":"2054","span":{"begin":482,"end":500},"obj":"Chemical"},{"id":"2117","span":{"begin":78,"end":86},"obj":"Disease"},{"id":"2118","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"2119","span":{"begin":776,"end":784},"obj":"Disease"},{"id":"2120","span":{"begin":911,"end":920},"obj":"Disease"}],"attributes":[{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"Tax:9606"},{"id":"A1886","pred":"tao:has_database_id","subj":"1886","obj":"Tax:9606"},{"id":"A2054","pred":"tao:has_database_id","subj":"2054","obj":"MESH:D006886"},{"id":"A2117","pred":"tao:has_database_id","subj":"2117","obj":"MESH:C000657245"},{"id":"A2118","pred":"tao:has_database_id","subj":"2118","obj":"MESH:C000657245"},{"id":"A2119","pred":"tao:has_database_id","subj":"2119","obj":"MESH:C000657245"},{"id":"A2120","pred":"tao:has_database_id","subj":"2120","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020"}